Comments
Loading...
Enliven Therapeutics Insider Trading Activity | NASDAQ:ELVN | Benzinga
Track the latest Enliven Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for Enliven Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Enliven Therapeutics Inc Insiders Doing?
At Enliven Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 31.67K shares worth $660.83K, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On March 11, 2025, Anish Patel, the company's CHIEF OPERATING OFFICER sold 6.67K shares for $21.44 each.
- On February 10, 2025, Anish Patel, the company's CHIEF OPERATING OFFICER sold 6.67K shares for $21.93 each.
- On March 21, 2025, Joseph Lyssikatos, the company's CHIEF SCIENTIFIC OFFICER sold 12.5K shares for $20.61 each.
Ownership Statistics for Enliven Therapeutics Inc
Shares Outstanding
49.004M
Insider Shares Owned
261.140K
Insider Percentage Owned
0.53%
Institutional Shares Held
17.162M
Institutional Percentage Held
35.0%
| Mar 21, 2025 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -12.50K | $20.61 | -$257.58K | SELL | -1.23% | 1.00M | Mar 19 | View |
| Mar 19, 2025 | Samuel Kintz | PRESIDENT AND CEO | -12.50K | $20.83 | -$260.32K | SELL | -1.25% | 990.39K | Mar 17 | View |
| Mar 11, 2025 | Anish Patel | CHIEF OPERATING OFFICER | -6.67K | $21.44 | -$142.94K | SELL | -2.02% | 323.31K | Mar 07 | View |
| Mar 03, 2025 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $11.44 | -$58.27K | SELL-OPTIONS | 0.00% | 13.00K | Feb 27 | View |
| Feb 10, 2025 | Anish Patel | CHIEF OPERATING OFFICER | -6.67K | $21.93 | -$146.21K | SELL | -1.98% | 329.98K | Feb 07 | View |
| Feb 07, 2025 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.50 | -$20.04K | SELL-OPTIONS | 0.00% | 13.00K | Feb 05 | View |
| Jan 29, 2025 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.04 | -$62.12K | SELL-OPTIONS | 0.00% | 13.00K | Jan 27 | View |
| Jan 10, 2025 | Anish Patel | CHIEF OPERATING OFFICER | -6.67K | $12.99 | -$646.60K | SELL | -1.94% | 336.64K | Jan 07 | View |
| Jan 07, 2025 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 13.00K | $13.76 | $9.68K | SELL-OPTIONS | ∞ | 13.00K | Dec 13 - Jan 03 | View |
| Dec 31, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.35 | -$83.93K | SELL-OPTIONS | 0.00% | 0.00 | Dec 27 - Dec 30 | View |
| Dec 02, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $13.69 | -$117.67K | SELL-OPTIONS | 0.00% | 0.00 | Nov 27 | View |
| Oct 30, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $15.52 | -$162.98K | SELL-OPTIONS | 0.00% | 0.00 | Oct 28 | View |
| Oct 22, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -716.00 | $30.00 | -$21.48K | SELL | -0.21% | 343.31K | Oct 18 | View |
| Oct 22, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -847.00 | $30.00 | -$25.41K | SELL | -0.08% | 1.02M | Oct 18 | View |
| Oct 22, 2024 | Samuel Kintz | PRESIDENT AND CEO | -924.00 | $30.00 | -$27.72K | SELL | -0.09% | 1.00M | Oct 18 | View |
| Oct 22, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $16.24 | -$22.40K | SELL-OPTIONS | 0.00% | 0.00 | Oct 18 | View |
| Oct 22, 2024 | Richard Heyman | — | -1.57K | $30.00 | -$47.10K | SELL | -2.37% | 64.57K | Oct 18 | View |
| Oct 22, 2024 | Louise Helen Collins | CHIEF MEDICAL OFFICER | 0.00 | $16.24 | -$22.46K | SELL-OPTIONS | 0.00% | 0.00 | Oct 18 | View |
| Oct 17, 2024 | Richard Heyman | — | -1.27K | $27.67 | -$35.14K | SELL | -0.83% | 152.41K | Oct 15 | View |
| Oct 10, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -51.15K | $28.11 | -$1.44M | SELL | -4.79% | 1.02M | Oct 08 - Oct 09 | View |
| Oct 10, 2024 | Samuel Kintz | PRESIDENT AND CEO | -29.98K | $28.07 | -$841.33K | SELL | -2.90% | 1.00M | Oct 08 - Oct 09 | View |
| Oct 10, 2024 | Rahul Ballal | — | 0.00 | $21.14 | -$146.63K | SELL-OPTIONS | 0.00% | 22.34K | Oct 08 | View |
| Oct 08, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -10.23K | $27.54 | -$281.66K | SELL | -0.95% | 1.07M | Oct 04 - Oct 07 | View |
| Oct 08, 2024 | Samuel Kintz | PRESIDENT AND CEO | -14.94K | $27.51 | -$410.87K | SELL | -1.42% | 1.03M | Oct 04 - Oct 07 | View |
| Oct 08, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $14.99 | -$287.52K | SELL-OPTIONS | 0.00% | 0.00 | Oct 04 - Oct 07 | View |
| Oct 08, 2024 | Richard Heyman | — | -2.83K | $27.51 | -$77.70K | SELL | -1.81% | 153.68K | Oct 04 | View |
| Oct 03, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -527.00 | $27.54 | -$14.51K | SELL | -0.05% | 1.08M | Oct 01 | View |
| Oct 03, 2024 | Samuel Kintz | PRESIDENT AND CEO | -526.00 | $27.54 | -$14.48K | SELL | -0.05% | 1.05M | Oct 01 | View |
| Oct 03, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $15.01 | -$13.05K | SELL-OPTIONS | 0.00% | 0.00 | Oct 01 | View |
| Oct 03, 2024 | Richard Heyman | — | -518.00 | $27.54 | -$14.26K | SELL | -0.33% | 156.50K | Oct 01 | View |
| Oct 01, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $13.55 | -$138.33K | SELL-OPTIONS | 0.00% | 0.00 | Sep 27 - Sep 30 | View |
| Sep 18, 2024 | Richard Heyman | — | -1.27K | $22.41 | -$28.46K | SELL | -0.80% | 157.02K | Sep 16 | View |
| Sep 03, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -12.00K | $22.49 | -$269.84K | SELL | -1.10% | 1.08M | Aug 29 | View |
| Aug 29, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.51 | -$85.24K | SELL-OPTIONS | 0.00% | 0.00 | Aug 27 | View |
| Aug 28, 2024 | Samuel Kintz | PRESIDENT AND CEO | -12.00K | $22.89 | -$274.72K | SELL | -1.13% | 1.05M | Aug 26 | View |
| Aug 19, 2024 | Richard Heyman | — | -1.27K | $23.25 | -$29.53K | SELL | -0.80% | 158.29K | Aug 15 | View |
| Aug 02, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -3.10K | $27.56 | -$85.40K | SELL | -0.28% | 1.09M | Jul 31 | View |
| Aug 02, 2024 | Samuel Kintz | PRESIDENT AND CEO | -2.27K | $27.56 | -$62.56K | SELL | -0.21% | 1.06M | Jul 31 | View |
| Aug 02, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $15.00 | -$24.82K | SELL-OPTIONS | 0.00% | 0.00 | Jul 31 | View |
| Aug 02, 2024 | Richard Heyman | — | -2.35K | $27.50 | -$64.66K | SELL | -3.47% | 65.33K | Jul 31 | View |
| Jul 31, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -12.00K | $26.70 | -$320.38K | SELL | -1.09% | 1.09M | Jul 29 | View |
| Jul 31, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $14.58 | -$127.03K | SELL-OPTIONS | 0.00% | 0.00 | Jul 29 | View |
| Jul 29, 2024 | Samuel Kintz | PRESIDENT AND CEO | -12.00K | $24.92 | -$299.07K | SELL | -1.03% | 1.15M | Jul 25 | View |
| Jul 17, 2024 | Richard Heyman | — | -1.27K | $24.80 | -$31.50K | SELL | -0.78% | 161.91K | Jul 15 | View |
| Jul 16, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -50.00K | $25.06 | -$1.25M | SELL | -12.69% | 344.03K | Jul 12 - Jul 16 | View |
| Jul 16, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $13.77 | -$67.75K | SELL-OPTIONS | 0.00% | 0.00 | Jul 12 | View |
| Jul 03, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | -12.00K | $22.89 | -$274.74K | SELL | -1.07% | 1.11M | Jul 01 | View |
| Jul 01, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.52 | -$85.38K | SELL-OPTIONS | 0.00% | 0.00 | Jun 27 | View |
| Jun 27, 2024 | Samuel Kintz | PRESIDENT AND CEO | -12.00K | $21.66 | -$259.90K | SELL | -1.02% | 1.16M | Jun 25 | View |
| Jun 20, 2024 | Richard Heyman | — | -1.27K | $21.48 | -$27.28K | SELL | -0.77% | 163.18K | Jun 17 | View |
| Jun 10, 2024 | Anish Patel | CHIEF OPERATING OFFICER | 0.00 | $11.27 | -$19.91K | SELL-OPTIONS | 0.00% | 394.03K | Jun 06 | View |
| May 31, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $11.43 | -$247.36K | SELL-OPTIONS | 0.00% | 1.12M | May 29 | View |
| May 30, 2024 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $12.15 | -$264.77K | SELL-OPTIONS | 0.00% | 88.53K | May 28 | View |
| May 30, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.83 | -$87.99K | SELL-OPTIONS | 0.00% | 0.00 | May 28 | View |
| May 20, 2024 | Richard Heyman | — | -1.27K | $23.74 | -$30.15K | SELL | -0.77% | 164.45K | May 16 | View |
| May 20, 2024 | Rishi Gupta | DIRECTOR | -1.03M | $22.14 | -$22.88M | SELL | -11.88% | 7.66M | May 16 | View |
| May 20, 2024 | ORBIMED ADVISORS LLCOrbiMed Capital GP VII LLCOrbiMed Genesis GP LLC | DIRECTOR | -1.03M | $22.14 | -$22.88M | SELL | -11.88% | 7.66M | May 16 | View |
| May 16, 2024 | Anish Patel | CHIEF OPERATING OFFICER | 0.00 | $13.74 | -$24.93K | SELL-OPTIONS | 0.00% | 394.03K | May 14 | View |
| May 13, 2024 | Anish Patel | CHIEF OPERATING OFFICER | 0.00 | $13.77 | -$5.87K | SELL-OPTIONS | 0.00% | 394.03K | May 09 | View |
| May 08, 2024 | Anish Patel | CHIEF OPERATING OFFICER | 0.00 | $12.60 | -$98.68K | SELL-OPTIONS | 0.00% | 394.03K | May 06 | View |
| May 07, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $12.49 | -$20.02K | SELL-OPTIONS | 0.00% | 0.00 | May 03 | View |
| May 01, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $9.52 | -$201.55K | SELL-OPTIONS | 0.00% | 1.12M | Apr 29 | View |
| May 01, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $9.73 | -$47.10K | SELL-OPTIONS | 0.00% | 0.00 | Apr 29 | View |
| Apr 29, 2024 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $9.01 | -$189.26K | SELL-OPTIONS | 0.00% | 88.53K | Apr 25 | View |
| Apr 15, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -2.60K | $13.76 | -$401.14K | SELL | -0.65% | 394.03K | Apr 11 | View |
| Apr 15, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $13.08 | -$717.73K | SELL-OPTIONS | 0.00% | 1.12M | Apr 11 | View |
| Apr 15, 2024 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $13.08 | -$1.14M | SELL-OPTIONS | 0.00% | 88.53K | Apr 11 | View |
| Apr 15, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $13.60 | -$311.43K | SELL-OPTIONS | 0.00% | 0.00 | Apr 11 | View |
| Apr 15, 2024 | Richard Heyman | — | -6.96K | $24.11 | -$167.89K | SELL | -9.55% | 65.97K | Apr 11 - Apr 15 | View |
| Apr 15, 2024 | Louise Helen Collins | CHIEF MEDICAL OFFICER | 0.00 | $13.78 | -$451.88K | SELL-OPTIONS | 0.00% | 0.00 | Apr 11 | View |
| Apr 12, 2024 | Rahul Ballal | — | 0.00 | $18.22 | -$688.19K | SELL-OPTIONS | 0.00% | 22.34K | Apr 10 - Apr 11 | View |
| Apr 10, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -4.88K | $18.60 | -$90.69K | SELL | -1.21% | 396.62K | Apr 08 | View |
| Apr 08, 2024 | Rahul Ballal | — | 0.00 | $15.87 | -$22.82K | SELL-OPTIONS | 0.00% | 22.34K | Apr 04 | View |
| Apr 03, 2024 | Rahul Ballal | — | 0.00 | $12.40 | -$43.22K | SELL-OPTIONS | 0.00% | 22.34K | Apr 01 | View |
| Apr 03, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $9.86 | -$209.71K | SELL-OPTIONS | 0.00% | 1.12M | Apr 01 | View |
| Mar 29, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $10.36 | -$51.24K | SELL-OPTIONS | 0.00% | 0.00 | Mar 27 | View |
| Mar 27, 2024 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $9.34 | -$197.22K | SELL-OPTIONS | 0.00% | 88.53K | Mar 25 | View |
| Mar 22, 2024 | Rahul Ballal | — | 0.00 | $12.34 | -$181.17K | SELL-OPTIONS | 0.00% | 22.34K | Mar 20 | View |
| Mar 21, 2024 | Richard Heyman | — | -1.27K | $14.50 | -$18.42K | SELL | -0.73% | 172.69K | Mar 19 | View |
| Mar 08, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -4.88K | $15.64 | -$76.24K | SELL | -1.20% | 401.50K | Mar 06 | View |
| Mar 04, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $8.77 | -$183.57K | SELL-OPTIONS | 0.00% | 1.12M | Feb 29 | View |
| Feb 29, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $9.73 | -$47.10K | SELL-OPTIONS | 0.00% | 0.00 | Feb 27 | View |
| Feb 28, 2024 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $9.00 | -$189.21K | SELL-OPTIONS | 0.00% | 88.53K | Feb 26 | View |
| Feb 20, 2024 | Richard Heyman | — | -1.27K | $17.42 | -$22.12K | SELL | -0.72% | 173.96K | Feb 15 | View |
| Feb 16, 2024 | AM Partners VI LLCAM Ventures VI LPAM Opportunities I GP LLCAM Opportunities I LPKUSH PARMARAndrew Schwab | 10% OWNER | -825.00K | $14.90 | -$12.29M | SELL | -56.49% | 635.34K | Feb 14 | View |
| Feb 08, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -4.88K | $15.11 | -$73.66K | SELL | -1.19% | 406.37K | Feb 06 | View |
| Feb 02, 2024 | AM Partners VI LLCAM Ventures VI LPAM Opportunities I GP LLCAM Opportunities I LPKUSH PARMARAndrew Schwab | 10% OWNER | -500.00K | $15.00 | -$7.50M | SELL | -39.31% | 771.98K | Jan 31 | View |
| Feb 01, 2024 | Richard Heyman | — | -1.27K | $16.41 | -$20.84K | SELL | -0.72% | 175.23K | Jan 30 | View |
| Jan 31, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $8.49 | -$176.82K | SELL-OPTIONS | 0.00% | 1.12M | Jan 29 | View |
| Jan 31, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $9.15 | -$43.33K | SELL-OPTIONS | 0.00% | 0.00 | Jan 29 | View |
| Jan 29, 2024 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $8.40 | -$174.79K | SELL-OPTIONS | 0.00% | 88.53K | Jan 25 | View |
| Jan 24, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -4.88K | $15.13 | -$73.78K | SELL | -1.17% | 411.25K | Jan 22 | View |
| Jan 03, 2024 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $7.70 | -$157.94K | SELL-OPTIONS | 0.00% | 1.12M | Dec 29 | View |
| Jan 02, 2024 | Anish Patel | CHIEF OPERATING OFFICER | -13.54K | $15.02 | -$203.35K | SELL | -3.15% | 416.12K | Dec 28 - Jan 02 | View |
| Jan 02, 2024 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $8.75 | -$148.89K | SELL-OPTIONS | 0.00% | 0.00 | Dec 28 - Jan 02 | View |
| Dec 28, 2023 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $7.88 | -$162.27K | SELL-OPTIONS | 0.00% | 88.53K | Dec 26 | View |
| Dec 27, 2023 | Anish Patel | CHIEF OPERATING OFFICER | -1.08K | $15.03 | -$16.31K | SELL | -0.25% | 429.66K | Dec 22 - Dec 26 | View |
| Dec 27, 2023 | Benjamin Hohl | CHIEF FINANCIAL OFFICER | 0.00 | $8.77 | -$14.22K | SELL-OPTIONS | 0.00% | 0.00 | Dec 22 - Dec 26 | View |
| Dec 26, 2023 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $7.09 | -$78.44K | SELL-OPTIONS | 0.00% | 1.12M | Dec 21 - Dec 22 | View |
| Dec 26, 2023 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $7.08 | -$97.74K | SELL-OPTIONS | 0.00% | 88.53K | Dec 21 - Dec 22 | View |
| Dec 26, 2023 | Richard Heyman | DIRECTOR | -216.00 | $13.00 | -$2.81K | SELL | -0.32% | 66.62K | Dec 21 - Dec 22 | View |
| Dec 21, 2023 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $7.07 | -$92.53K | SELL-OPTIONS | 0.00% | 88.53K | Dec 20 | View |
| Dec 21, 2023 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $7.07 | -$105.69K | SELL-OPTIONS | 0.00% | 1.12M | Dec 19 - Dec 20 | View |
| Dec 21, 2023 | Richard Heyman | DIRECTOR | -4.28K | $13.02 | -$55.73K | SELL | -6.03% | 66.66K | Dec 19 - Dec 20 | View |
| Nov 06, 2023 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $7.10 | -$102.18K | SELL-OPTIONS | 0.00% | 1.12M | Nov 03 | View |
| Nov 06, 2023 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $7.10 | -$96.01K | SELL-OPTIONS | 0.00% | 88.53K | Nov 03 | View |
| Oct 03, 2023 | Joseph Lyssikatos | CHIEF SCIENTIFIC OFFICER | 0.00 | $7.37 | -$150.06K | SELL-OPTIONS | 0.00% | 1.12M | Sep 29 | View |
| Sep 28, 2023 | AM Partners VI LLCAM Ventures VI LPAM Opportunities I GP LLCAM Opportunities I LPKUSH PARMARAndrew Schwab | 10% OWNER | -197.50K | $15.00 | -$2.96M | SELL | -18.77% | 854.80K | Sep 26 | View |
| Sep 26, 2023 | Samuel Kintz | PRESIDENT AND CEO | 0.00 | $7.46 | -$152.25K | SELL-OPTIONS | 0.00% | 88.53K | Sep 25 | View |
| Aug 28, 2023 | AM Partners VI LLCAM Ventures VI LPAM Opportunities I GP LLCAM Opportunities I LPKUSH PARMARAndrew Schwab | 10% OWNER | -440.00K | $16.00 | -$7.04M | SELL | -33.14% | 887.51K | Aug 24 | View |
| Feb 27, 2023 | COMMODORE CAPITAL LP | 10% OWNER | 730.51K | $22.07 | $13.72K | BUY | 101.72% | 1.45M | Feb 23 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.